You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Practical guidance to support vaccination during the COVID-19 pandemic

4th August 2020 | 12:30 PM

Market research was commissioned by GSK and carried out amongst 2,511 parents of children aged between 9 months and 10 years old during May 2020. It suggests that despite 93% of parents being generally happy for their children to be vaccinated, only 78% of them are happy for their child to have vaccinations during the Covid-19 pandemic. 1 The experts will explore how to address some of the concerns raised by parents along with preparing for the 2020/21 seasonal flu vaccination programme.

Q&A session from Practical guidance to support vaccination during the COVID-19 pandemic

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/UK/MP4/gsk-vaccines-only-qa-np-gb-mlv-ogm-200001.mp4

The information that was provided by the panel during the Q&A was relevant at the time of the webinar on the 4th August 2020

Speakers

Isabel Robson GSK

Isabel is the Medical Engagement Strategy Lead at GSK in the vaccines team and is therefore committed to explore practical solutions to remove vaccination barriers in the UK, Isabel is involved in numerous projects throughout the UK, to highlight the value of vaccination to healthcare professionals and the general public.

Dr Catherine Heffernan

Principal Advisor for Commissioning Early Years, Immunisations and Vaccination Services.
Catherine Heffernan is a Consultant at Public Health England and since 2013, she has been the Principal Advisor for Commissioning Early Years, Immunisations and Vaccination Services advising NHS England (London Region) on commissioning Section 7a immunisation programmes.

Dr Philip Cruz GSK Medical Director UK and Ireland

Dr Philip Cruz is trained in paediatrics in the Philippines and has been working in the pharmaceutical industry for 15 years. He joined GSK in 2010 as a senior medical manager and has the opportunity to interact with Ministries of Health, technical advisory groups and local experts to ascertain the public health burden of vaccine preventable paediatric diseases across Asia and the Emerging markets region. Dr Cruz then moved to his current role of medical director in 2015 to further support the clinical and medical affairs initiatives of GSK vaccines in the UK and Ireland.

Reference:

  1. GSK Data on File Vaccines in Light of Covid-19 Market Research May 2020.

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk/ or search for MHRA.
Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on +44 (0)800 221 441.